Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts
1998

Combining Lonidamine and Cisplatin for Cancer Treatment

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): M De Cesare, G Pratesi, A Giusti, D Polizzi, F Zunino

Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori

Hypothesis

Does the combination of lonidamine and cisplatin enhance the apoptotic response in human tumor xenografts?

Conclusion

The combination of lonidamine and cisplatin is more effective in inhibiting tumor growth and inducing apoptosis in sensitive tumors compared to cisplatin alone.

Supporting Evidence

  • The combination of lonidamine and cisplatin significantly enhanced tumor volume inhibition compared to cisplatin alone.
  • Lonidamine increased the apoptotic response induced by cisplatin in sensitive tumors.
  • Phosphorylation of bcl-2 was associated with the efficacy of the drug combination.

Takeaway

This study found that using lonidamine with cisplatin helps kill cancer cells better than using cisplatin by itself.

Methodology

The study used human tumor xenografts in nude mice to assess the effects of lonidamine and cisplatin on tumor growth and apoptosis.

Limitations

The study focused only on specific carcinoma models and may not generalize to all tumor types.

Participant Demographics

Female athymic nude CD-1 mice were used for the experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication